159 related articles for article (PubMed ID: 21737212)
1. [Hematogenous dissemination in epithelial ovarian cancer: case report].
Bijek JH; Ehnart N; Mathevet P
J Gynecol Obstet Biol Reprod (Paris); 2011 Sep; 40(5):465-8. PubMed ID: 21737212
[TBL] [Abstract][Full Text] [Related]
2. Hematogenous rectal metastasis 20 years after removal of epithelial ovarian cancer.
Trastour C; Rahili A; Schumacker C; Effi AB; Bernard JL
Gynecol Oncol; 2004 Aug; 94(2):584-8. PubMed ID: 15297210
[TBL] [Abstract][Full Text] [Related]
3. AEG -1 overexpression: a novel indicator for peritoneal dissemination and lymph node metastasis in epithelial ovarian cancers.
Li C; Liu J; Lu R; Yu G; Wang X; Zhao Y; Song H; Lin P; Sun X; Yu X; Zhang Y; Ning X; Geng J
Int J Gynecol Cancer; 2011 May; 21(4):602-8. PubMed ID: 21543927
[TBL] [Abstract][Full Text] [Related]
4. The effect of age on first-line chemotherapy for epithelial ovarian cancer and primary peritoneal carcinoma.
Larbi E; Madhuri K; Essapen S; Butler-Manuel S; Tailor A; Michael A
Clin Oncol (R Coll Radiol); 2013 Jan; 25(1):75. PubMed ID: 23146339
[No Abstract] [Full Text] [Related]
5. Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.
Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Ohishi R; Hasegawa K; Goto T; Fujiwara K
Int J Gynecol Cancer; 2012 Jan; 22(1):70-5. PubMed ID: 22146766
[TBL] [Abstract][Full Text] [Related]
6. Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression.
Steffensen KD; Smoter M; Waldstrøm M; Grala B; Bodnar L; Stec R; Szczylik C; Jakobsen A
Int J Oncol; 2014 May; 44(5):1736-44. PubMed ID: 24585004
[TBL] [Abstract][Full Text] [Related]
7. [Effect of evidence-based medicine on the decision of chemotherapy for epithelial ovarian cancer].
Li GT
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):582-6. PubMed ID: 23141177
[No Abstract] [Full Text] [Related]
8. Increased expression of heat shock protein 27 correlates with peritoneal metastasis in epithelial ovarian cancer.
Zhao M; Shen F; Yin YX; Yang YY; Xiang DJ; Chen Q
Reprod Sci; 2012 Jul; 19(7):748-53. PubMed ID: 22534325
[TBL] [Abstract][Full Text] [Related]
9. Paraaortic node recurrence 25 years after removal of epithelial ovarian carcinoma.
Otsuka I; Shoji K
J Obstet Gynaecol Res; 2016 Nov; 42(11):1609-1612. PubMed ID: 27641229
[TBL] [Abstract][Full Text] [Related]
10. The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression.
Deng J; Wang L; Chen H; Li L; Ma Y; Ni J; Li Y
Cancer Metastasis Rev; 2013 Dec; 32(3-4):535-51. PubMed ID: 23609751
[TBL] [Abstract][Full Text] [Related]
11. Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC).
Seifert H; Georgiou A; Alexander H; McLachlan J; Bodla S; Kaye S; Barton D; Nobbenhuis M; Gore M; Banerjee S
Gynecol Oncol; 2015 Nov; 139(2):216-20. PubMed ID: 26318078
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy fails to improve survival in advanced ovarian cancer: but is it the real culprit?
Di Giorgio A; Sammartino P; Biacchi D
Int J Gynecol Cancer; 2011 May; 21(4):596. PubMed ID: 21543925
[No Abstract] [Full Text] [Related]
13. Prognostic factors in epithelial ovarian cancer: A population-based study.
Chang LC; Huang CF; Lai MS; Shen LJ; Wu FL; Cheng WF
PLoS One; 2018; 13(3):e0194993. PubMed ID: 29579127
[TBL] [Abstract][Full Text] [Related]
14. Paraparesis: a rare primary presentation of epithelial ovarian cancer.
Wuntkal R; Maheshwari A; Gupta S; Tongaonkar H
Int J Gynecol Cancer; 2006; 16 Suppl 1():293-4. PubMed ID: 16515606
[TBL] [Abstract][Full Text] [Related]
15. Role of human epididymis protein 4 in chemoresistance and prognosis of epithelial ovarian cancer.
Lee S; Choi S; Lee Y; Chung D; Hong S; Park N
J Obstet Gynaecol Res; 2017 Jan; 43(1):220-227. PubMed ID: 27862665
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the specificity of a new folate-targeted photosensitizer for peritoneal metastasis of epithelial ovarian cancer to enable intraperitoneal photodynamic therapy. A preclinical study.
Azaïs H; Schmitt C; Tardivel M; Kerdraon O; Stallivieri A; Frochot C; Betrouni N; Collinet P; Mordon S
Photodiagnosis Photodyn Ther; 2016 Mar; 13():130-138. PubMed ID: 26200606
[TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
[TBL] [Abstract][Full Text] [Related]
18. Low-grade epithelial ovarian cancer: a number of distinct clinical entities?
Oswald AJ; Gourley C
Curr Opin Oncol; 2015 Sep; 27(5):412-9. PubMed ID: 26241347
[TBL] [Abstract][Full Text] [Related]
19. [Potential value of CA125 kinetic monitoring in the initial management of advanced epithelial ovarian cancer].
Vignot S; Brochet C; Debord C; Lauratet B; Bernard M
Ann Biol Clin (Paris); 2011; 69(5):597-604. PubMed ID: 22008142
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute.
Hainsworth JD; Thompson DS; Bismayer JA; Gian VG; Merritt WM; Whorf RC; Finney LH; Dudley BS
Cancer Med; 2015 May; 4(5):673-81. PubMed ID: 25556916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
